- Study: Teens and young adults respond well to learning about familial cancer risk
- [No author given]
- FORCE. XRAY. 2022 Oct 11.
- Research news
- Free Full Text
Original research:
Long-Term Adaptation Among Adolescent and Young Adult Children to Familial Cancer Risk.
- PMID: 35859209
- PubMed abstract
- Source abstract
Commentary:
Breaking Down the Barriers of Hereditary Cancer Risk Disclosure in AYA.
- PMID: 35859132
- PubMed abstract
- Source abstract
- Validation of the modified Chinese Information and Support Needs Questionnaire (ISNQ-C) for daughters of mothers with breast cancer.
- Fang SY, Chen TC.
- Palliat Support Care. 2022 Oct 11:1-9. doi: 10.1017/S1478951522001407. Epub ahead of print.
- PMID: 36217687
- PubMed abstract
- Source abstract
- A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome.
- Kai M, Kubo M, Shikada S, Hayashi S, Morisaki T, Yamada M, Takao Y, Shimazaki A, Harada Y, Kaneshiro K, Mizuuchi Y, Shindo K, Nakamura M.
- Surg Case Rep. 2022 Oct 11;8(1):197. doi: 10.1186/s40792-022-01546-y.
- PMID: 36219266
- PubMed abstract
- Case report
- Free Full Text
- Validation of the Nigerian Breast Cancer Study Model for Predicting Individual Breast Cancer Risk in Cameroon and Uganda.
- Ashi K, Ndom P, Gakwaya A, Makumbi T, Olopade OI, Huo D.
- Cancer Epidemiol Biomarkers Prev. 2022 Oct 10:EPI-22-0869. doi: 10.1158/1055-9965.EPI-22-0869. Epub ahead of print.
- PMID: 36215182
- PubMed abstract
- Source abstract
- Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations.
- Dietrich M, Ball E, McKenzie A, Vidal G.
- OncLive. Peer Exchange. 2022 Oct 10.
- Review. Video
- Free video
- Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
- Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA.
- Onco Targets Ther. 2022 Oct 4;15:1105-1117. doi: 10.2147/OTT.S272199.
- PMID: 36217436
- PubMed abstract
- Review
- Free PMC article
- Free Full Text